1. Home
  2. LRE vs CTXR Comparison

LRE vs CTXR Comparison

Compare LRE & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lead Real Estate Co. Ltd

LRE

Lead Real Estate Co. Ltd

N/A

Current Price

$1.35

Market Cap

17.2M

Sector

N/A

ML Signal

N/A

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.76

Market Cap

16.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LRE
CTXR
Founded
2001
2007
Country
Japan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.2M
16.8M
IPO Year
2022
2010

Fundamental Metrics

Financial Performance
Metric
LRE
CTXR
Price
$1.35
$0.76
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
25.3K
636.8K
Earning Date
07-30-2015
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.38
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$147.57
P/E Ratio
$3.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$0.63
52 Week High
$2.86
$2.38

Technical Indicators

Market Signals
Indicator
LRE
CTXR
Relative Strength Index (RSI) 52.00 45.08
Support Level $1.34 $0.70
Resistance Level $1.43 $0.99
Average True Range (ATR) 0.09 0.10
MACD 0.00 -0.01
Stochastic Oscillator 30.87 13.32

Price Performance

Historical Comparison
LRE
CTXR

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: